Viewing stories from July, 2020

Quarterly Cashflow and Activities Report

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 June 2020.

DEP® docetaxel and gemcitabine combination trial commences

Starpharma today announced that it has commenced its DEP® docetaxel + gemcitabine combination study for patients with advanced cancers, including pancreatic cancer. Recruitment into the study has commenced at the Christie in the UK, with two further sites expected to open in the coming weeks.

 

AZD0466 trial opens MD Anderson Cancer Center as a site

Starpharma (ASX: SPL, OTCQX: SPHRY) today announced the opening of the MD Anderson Cancer Center as a further trial site for the phase 1 trial of AZD0466, AstraZeneca’s first DEP® product.

New Australian site opening for DEP® trials

Starpharma today announced the opening of a new trial site for the phase 2 DEP® irinotecan trial, at the Kinghorn Cancer Centre in Sydney. The DEP® irinotecan trial is also being conducted at multiple leading UK cancer centres including The Christie, The Royal Marsden, Newcastle Freeman Hospital, and The Beatson West of Scotland Cancer Centre. The Kinghorn Cancer Centre will also be opened shortly as an additional site for the phase 2 DEP® cabazitaxel trial.

 

Pandemic A Catalyst For Homegrown Remedies Says Starpharma Boss

The Age interviewed Starpharma CEO Dr Jackie Fairley about how the COVID-19 pandemic could be the much needed catalyst for the pharmaceutical industry to improve the way they convert important research into commercial products. Dr Fairley also covered Starpharma’s recent activities in response to the pandemic including, the development of a nasal spray product using the antiviral dendrimer, SPL7013.

To read the full interview click here.

Pandemic a catalyst for boosting commercial outcomes, says Starpharma CEO

The Age recently interviewed Starpharma CEO Dr Jackie Fairley to discuss how the COVID19 pandemic could be the catalyst for the pharmaceutical industry to improve the way they convert important research into commercial products. The article highlighted Starpharma’s recent activities in response to the pandemic, including the development of a product using its existing anti-viral dendrimer SPL7013.

To read the full article, click here.

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.